Fredun Pharmaceuticals Board Meets on May 15, 2026 to Review Q4 FY26 Monitoring Agency Report

Fredun Pharmaceuticals Limited convened a Board of Directors meeting on Friday, May 15, 2026, conducted through Video Conferencing (VC). The meeting was held in compliance with Regulation 30 of Schedule III of the SEBI (Listing Obligations & Disclosure Requirements) Regulations, 2015, and the outcome was formally disclosed to BSE Limited.

Board Meeting Overview

The Board meeting commenced at 07:30 P.M. and concluded at 08:00 P.M. on May 15, 2026. The key business transacted during the session is outlined below:

Parameter:	Details
Meeting Date:	Friday, May 15, 2026
Mode of Meeting:	Video Conferencing (VC)
Commencement Time:	07:30 P.M.
Conclusion Time:	08:00 P.M.
Agenda Item:	Monitoring Agency Report for Q4 FY26
Quarter Covered:	Quarter ended March 31, 2026
Regulatory Framework:	Regulation 30, Schedule III, SEBI (LODR) Regulations, 2015

Key Business Transacted

The sole agenda item addressed during the meeting was the review of the Monitoring Agency Report for the quarter ended March 31, 2026. The Board took note of the report as part of its statutory and regulatory obligations under the applicable SEBI listing regulations.

The disclosure was signed by Fredun Nariman Medhora, Managing Director, from Mumbai, and submitted to the Corporate Relationship Department of BSE Limited at Phiroze Jeejeebhoy Towers, Dalal Street, Mumbai – 400 001.

1 Day	5 Days	1 Month	6 Months	1 Year	5 Years
-1.01%	+0.10%	+30.05%	+32.35%	+245.49%	+423.72%

Fredun Pharmaceuticals Limited has notified the BSE of an upcoming board meeting scheduled for Monday, May 25, 2026, in accordance with Regulation 29 read with Regulation 33 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The intimation, dated May 15, 2026, was submitted by Director Fredun Nariman Medhora (DIN: 01745348).

Key Agenda Items

The board meeting has been convened to deliberate on several significant matters pertaining to the financial year ended March 31, 2026. The following items are on the agenda:

Agenda Item:	Details
Financial Results:	Audited Financial Results & Statements (Standalone & Consolidated) for Q4 and FY ended March 31, 2026
Final Dividend:	Consider and recommend final dividend on paid-up equity shares for FY ended March 31, 2026
Bonus Equity Shares:	Consider and recommend Bonus Equity Shares, subject to approval of Members of the Company

Trading Window Closure

In compliance with the Securities and Exchange Board of India (Prohibition of Insider Trading) Regulations, 2015, the trading window for dealing in securities of Fredun Pharmaceuticals shall remain closed until the expiry of 48 hours after the declaration of the financial results. Market participants and insiders are advised to take note of this restriction accordingly.

Regulatory Compliance

The board meeting intimation has been filed in accordance with applicable SEBI listing regulations. The notice was digitally signed by Director Fredun Nariman Medhora on May 15, 2026, at 11:37:00 IST, confirming the company's adherence to disclosure requirements under the applicable regulatory framework.